Japanese pharmaceutical company Shionogi will sign a licensing agreement this month aimed at mass-producing a proposed coronavirus test that provides faster results without requiring special equipment or technicians.
A team led by Japanese biotech venture AnGes will ready production capacity for 1 million doses of coronavirus vaccines by March, a fivefold increase from the original plan, in order to ensure swift access to the domestic population.
Japan's Nippon Sheet Glass has converted a kit used to prevent food poisoning outbreaks into a diagnostic test for the novel coronavirus capable of returning results in as little as 10 minutes.
A university team has succeeded in the first-ever mass proliferation of rainbow trout germ line stem cells (GSCs) in vitro, a technique that could pave the way for preservation of endangered fish and enable their mass production.
Washing your hands in a perfunctory fashion won't pass go with a new artificial intelligence system, particularly at the time of a pandemic.
Japanese biotech AnGes Inc. expects its coronavirus vaccine to be ready as early as the first half of 2021, if it can overcome supply chain and production hurdles, the company’s founder said.
When minutes count in saving lives, a system pioneered in Japan called D-Call Net is making all the difference.
Japanese biotechnology company Takara Bio has developed a method to simultaneously process more than 5,000 polymerase chain reaction tests, which can screen for the new coronavirus, in just under two hours.